In view of the immune dysregulation profile seen in advanced MF/SS with a diminished Th1 immune response (IFN-gamma, IL-12) and skewing towards a Th2 immune profile (increased IL-4, IL-5 and/or IL-13) (80), interferons (IFN-alpha and IFN-gamma) were amongst the first immunotherapies to be used. This evidence concerns the gene IFNG and mycosis fungoides.